The June edition of Editors’ Picks from the AACR journals included studies on targeting neural cross-talk to stop glioblastoma recurrence, identifying patients with multiple myeloma who may benefit from debulking chemotherapy, examining considerable improvements...
A new report details persistent disparities in cancer care, and the FDA approved an antibody-drug conjugate as a first-line treatment for advanced triple-negative breast cancer.
At the AACR Annual Meeting 2026, a session highlighted progress from four Cancer Grand Challenges teams on the interplay of mutations, promoting factors, and tissue-specific epigenetic programs in cancer development and on the biology...
The AACR Cancer Disparities Progress Report 2026 included an examination of the growing gap in cancer care between rural and urban areas. The report also featured the stories of several cancer survivors—including Dennis Gruenhagen,...
The cochairs of the AACR Special Conference on Breaking Barriers in the Fight Against Rare Cancers—Andrew Futreal, PhD, FAACR, of The University of Texas MD Anderson Cancer Center; Taran Gujral, PhD, of Fred Hutch...
Scientists seek to understand relationship between viral infections and cancer recurrence, and breast cancer survivors seek menopause-symptom relief.
Can AI agents do cancer research? Many AI-centric research teams currently believe that with the right training, AI agents can in fact rise to the level of “co-scientists,” including Jure Leskovec, PhD, of Stanford...
Chenia Lloyd-Gascho, who was diagnosed with Li-Fraumeni syndrome when he was 8 years old, shared what it is like to grow up knowing you will one day get cancer, the routine monitoring recommended to...
Melanoma expert Ashani T. Weeraratna, PhD, of Johns Hopkins Bloomberg School of Public Health, explains how bemotrizinol—the first new sunscreen ingredient to be approved by the FDA in over 25 years—compares with currently used...
New studies show cancer vaccine promise despite funding cuts, and researchers identify protein signature that helps predict lung cancer risk.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn More